Back to Journals » Breast Cancer: Targets and Therapy
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
- View all (490)
- Volume 16, 2024 (19)
- Volume 15, 2023 (79)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Journal Articles:
- 490 records -
Correlation Analysis of Digital Mammography, Ultrasonography, and Pathologic Features in Pure Invasive Micropapillary Carcinoma of the Breast (PIMPC)
Sui X, Feng P, Sun X, Liang P, Liu Y, Zhang G
Breast Cancer: Targets and Therapy 2024, 16:245-252
Published Date: 25 April 2024
Expression and Significance of LINC02418 in Breast Cancer
Zhou YH, Huang JY
Breast Cancer: Targets and Therapy 2024, 16:233-243
Published Date: 24 April 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]
Syahruddin FI, Prihantono, Muis M
Breast Cancer: Targets and Therapy 2024, 16:221-222
Published Date: 11 April 2024
Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer
Ma S, Hao R, Lu YW, Wang HP, Hu J, Qi YX
Breast Cancer: Targets and Therapy 2024, 16:199-219
Published Date: 12 April 2024
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review
Ye M, Xu H, Ding J, Jiang L
Breast Cancer: Targets and Therapy 2024, 16:181-197
Published Date: 10 April 2024
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients
Wang S, Chen Y, Li W, Hao C, Zhang L, Zhao W, Shi Y, Tong Z
Breast Cancer: Targets and Therapy 2024, 16:163-179
Published Date: 3 April 2024
Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer
Ubowski MM, VanSice R, Marriott M, Yacobucci MJ, Chablani L
Breast Cancer: Targets and Therapy 2024, 16:149-162
Published Date: 28 March 2024
HER2 Low Expression in Primary Male Breast Cancer
Nobbe K, Erices-Leclercq M, Foerster F, Förster R, Baldus SE, Rudlowski C, Schröder L, Lubig S
Breast Cancer: Targets and Therapy 2024, 16:141-148
Published Date: 28 March 2024
ZNF217 Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer
Rangel N, Sánchez IL, Valbuena DS, Rondón-Lagos M
Breast Cancer: Targets and Therapy 2024, 16:127-139
Published Date: 15 March 2024
The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients
Ma Q, Liu YB, She T, Liu XL
Breast Cancer: Targets and Therapy 2024, 16:117-126
Published Date: 8 March 2024
Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, Drizon A, Chodick G, Siegelmann-Danieli N
Breast Cancer: Targets and Therapy 2024, 16:105-116
Published Date: 6 March 2024
An Analysis of Preoperative Inflammatory Indicators That Influence the Drainage Tube Retention Time in Patients with Breast Cancer Surgery
Li Q, Gao C, Zhao X, Li J, Shen Q, Chen L
Breast Cancer: Targets and Therapy 2024, 16:91-103
Published Date: 6 March 2024
GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer
Zhou Y, Xue W, Meng X, Bhandari A, Zeng H, KC R, Hirachan S, Xia E
Breast Cancer: Targets and Therapy 2024, 16:71-89
Published Date: 5 March 2024
Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
Monteiro MR, Nunes NCC, Junior AADS, Fêde ABDS, Bretas GDO, Souza CDP, Mano M, da Silva JL
Breast Cancer: Targets and Therapy 2024, 16:51-70
Published Date: 28 February 2024
Does Nipple-Ward Positive Margin Contribute to a Higher Rate of Re-Excision Procedures After a Lumpectomy with Pathology-Confirmed Positive Margins? A Retrospective Study
Bhimani F, Lin S, McEvoy M, Cavalli A, Obaid L, Chen Y, Gupta A, Pastoriza J, Shihabi A, Feldman S
Breast Cancer: Targets and Therapy 2024, 16:41-50
Published Date: 21 February 2024
Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse Disease-Free Survival in Patients with Breast Cancer
Chen CC, Tang WH, Wu CC, Lee TL, Tsai IT, Hsuan CF, Wang CP, Chung FM, Lee YJ, Yu TH, Wei CT
Breast Cancer: Targets and Therapy 2024, 16:23-39
Published Date: 16 January 2024
Thyroid Hormone Changes Correlate to Combined Breast Cancer with Primary Thyroid Cancer
Jin J, Li J, Liu Y, Shi Q, Zhang B, Ji Y, Hu P
Breast Cancer: Targets and Therapy 2024, 16:15-22
Published Date: 9 January 2024
The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors
Ekemen S, Bilir E, Soultan HEA, Zafar S, Demir F, Tabandeh B, Toprak S, Yapicier O, Coban C
Breast Cancer: Targets and Therapy 2024, 16:1-13
Published Date: 3 January 2024
CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1
Zhu X, Yu J, Ai F, Wang Y, Lv W, Yu G, Cao X, Lin J
Breast Cancer: Targets and Therapy 2023, 15:967-984
Published Date: 28 December 2023
Retrospective Analysis of the Clinical Characteristics of Patients with Breast Cancer Treated with Telomerase Peptide Immunotherapy Combined with Cytotoxic Chemotherapy
Kim JY, Yang DW, Kim S, Choi JG
Breast Cancer: Targets and Therapy 2023, 15:955-966
Published Date: 21 December 2023
The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]
Wardoyo S, Fadillah MA, Hamtini
Breast Cancer: Targets and Therapy 2023, 15:953-954
Published Date: 19 December 2023
Immunotherapy: Constructive Approach for Breast Cancer Treatment
Anayyat U, Ahad F, Muluh TA, Zaidi SAA, Usmani F, Yang H, Li M, Hassan HA, Wang X
Breast Cancer: Targets and Therapy 2023, 15:925-951
Published Date: 15 December 2023
Breast Cancer Awareness Among Women in Saudi Arabia: A Systematic Review
AlRajhi B, Aljadani FF, Almarwan SR, Alzahrani AA, Sindi MHM, Kano A, Alzahrani RS, Baaqeel R
Breast Cancer: Targets and Therapy 2023, 15:913-924
Published Date: 14 December 2023
The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models
Hu W, Wang L, Luo J, Zhang J, Li N
Breast Cancer: Targets and Therapy 2023, 15:899-912
Published Date: 8 December 2023
Accuracy Rate of Methylene Blue Injection in Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Patients: A Prospective Observational Study
Aziz HK, Azhar Y, Widarda IR, Abdurahman M, Erdiansyah Z, Nugraha P, Lukman K
Breast Cancer: Targets and Therapy 2023, 15:891-897
Published Date: 7 December 2023
Evaluation of Cytotoxicity of the Methanolic Extract of Red Sea Marine Sponge Xestospongia Testudinaria and Its Related Compounds Against MCF-7 Human Breast Cancer Cells
Alkhilaiwi FA, Fadil SA, Aljoud FA, Yonbawi AR, Ashi A, Hareeri RH, Bakhashab S, Alamri AM, Albikairi AY, Shaala LA, El-Gamal AA, Youssef DT
Breast Cancer: Targets and Therapy 2023, 15:879-890
Published Date: 7 December 2023
Nomogram Based on Super-Resolution Ultrasound Images Outperforms in Predicting Benign and Malignant Breast Lesions
Yang L, Ma Z
Breast Cancer: Targets and Therapy 2023, 15:867-878
Published Date: 2 December 2023
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy
Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA
Breast Cancer: Targets and Therapy 2023, 15:855-865
Published Date: 17 November 2023
Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
Huang J, Zhu W, Duan Q, Zhu C, Shi X, Zhao H, Cai P, Li D
Breast Cancer: Targets and Therapy 2023, 15:841-853
Published Date: 17 November 2023
The Emerging Roles of Exosomal miRNAs in Breast Cancer Progression and Potential Clinical Applications
Li J, He D, Bi Y, Liu S
Breast Cancer: Targets and Therapy 2023, 15:825-840
Published Date: 16 November 2023
Psychometric Properties and Factorial Analysis of the Arabic McGill-QoL Questionnaire in Breast Cancer
Omar MTA, Alnahdi AH
Breast Cancer: Targets and Therapy 2023, 15:813-824
Published Date: 14 November 2023
ABCB1 Regulates Immune Genes in Breast Cancer
Chen HK, Chen YL, Wang CY, Chung WP, Fang JH, Lai MD, Hsu HP
Breast Cancer: Targets and Therapy 2023, 15:801-811
Published Date: 13 November 2023
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T
Breast Cancer: Targets and Therapy 2023, 15:785-799
Published Date: 6 November 2023
Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
Gorenšek R, Kresnik M, Takač I, Rojko T, Sobočan M
Breast Cancer: Targets and Therapy 2023, 15:773-783
Published Date: 2 November 2023
A Review on the Management of Peripheral Neuropathic Pain Following Breast Cancer
Avila F, Torres-Guzman R, Maita K, Garcia JP, De Sario GD, Borna S, Ho OA, Forte AJ
Breast Cancer: Targets and Therapy 2023, 15:761-772
Published Date: 30 October 2023
Traditional Chinese Medicine for Breast Cancer: A Review
Feng RQ, Li DH, Liu XK, Zhao XH, Wen QE, Yang Y
Breast Cancer: Targets and Therapy 2023, 15:747-759
Published Date: 27 October 2023
PDL1-Based Nomogram May Be of Potential Clinical Utility for Predicting Survival Outcome in Stage III Breast Cancer
Zhang X, Li R, Wang G
Breast Cancer: Targets and Therapy 2023, 15:731-746
Published Date: 25 October 2023
Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives
Wang J, Wu SG
Breast Cancer: Targets and Therapy 2023, 15:721-730
Published Date: 20 October 2023
A Comprehensive Model Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging Can Better Predict the Preoperative Histological Grade of Breast Cancer Than a Radiomics Model
Wu Y, Pan W, Wang L, Pan W, Zhang H, Jin S, Wu X, Liu A, Xin E, Ji W
Breast Cancer: Targets and Therapy 2023, 15:709-720
Published Date: 18 October 2023
Hsa_circ_0007823 Overexpression Suppresses the Progression of Triple-Negative Breast Cancer via Regulating miR-182-5p-FOXO1 Axis
Yu J, Wang H, Shen W, Zhou Y, Cui J, Li H, Gao B
Breast Cancer: Targets and Therapy 2023, 15:695-708
Published Date: 18 October 2023
The Impact of Deep Inspiration Breath Hold (DIBH) Implementation on the Hybrid Technique in Left-Sided Whole Breast Irradiation: A Dosimetric Characteristic Study of 3D-CRT Hybrid VMAT in DIBH and Free Breathing Conditions, and VMAT in Free Breathing Conditions
Yeh HL, Lin JF
Breast Cancer: Targets and Therapy 2023, 15:683-693
Published Date: 12 October 2023
Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study
Chen X, Qian X, Xiao M, Zhang P
Breast Cancer: Targets and Therapy 2023, 15:671-682
Published Date: 4 September 2023
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
Ünal Ç, Özmen T, İlgün AS, Ordu Ç, Özkurt E, Ak N, Alço G, Erdoğan İyigün Z, Kurt S, Duymaz T, Öztürk MA, Elbüken Çelebi F, Yararbaş K, Soybir G, Aktepe F, Özmen V
Breast Cancer: Targets and Therapy 2023, 15:659-669
Published Date: 1 September 2023
Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
Tong L, Yu X, Wang S, Chen L, Wu Y
Breast Cancer: Targets and Therapy 2023, 15:647-658
Published Date: 24 August 2023
Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan
Haque R, Chen LH, Oestreicher N, Lalla D, Chlebowski RT
Breast Cancer: Targets and Therapy 2023, 15:637-645
Published Date: 16 August 2023
ABVS-Based Radiomics for Early Predicting the Efficacy of Neoadjuvant Chemotherapy in Patients with Breast Cancers
Jiang W, Deng X, Zhu T, Fang J, Li J
Breast Cancer: Targets and Therapy 2023, 15:625-636
Published Date: 15 August 2023
Diagnostic Value of a Combined Serum α-Hydroxybutyrate Dehydrogenase, Carcinoembryonic Antigen and Glycoantigen 125 Test for Early-Stage Breast Cancer
Zhan CH, Liu GJ
Breast Cancer: Targets and Therapy 2023, 15:617-623
Published Date: 15 August 2023
HER2-Low Breast Cancer: Current Landscape and Future Prospects
Shirman Y, Lubovsky S, Shai A
Breast Cancer: Targets and Therapy 2023, 15:605-616
Published Date: 14 August 2023
Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy
Fan J, Tang Y, Wang K, Yang S, Ma B
Breast Cancer: Targets and Therapy 2023, 15:591-604
Published Date: 11 August 2023